ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform
CSO Neil Cashman’s overview of ProMIS’ unique capability to selectively target toxic, misfolded proteins that are root causes of neurodegenerative diseases